Session 2: Where are we with NAMs, and why? – A US perspective

In this session, we discussed the current momentum in the US with a focus on the role of NAMs to address the problem of translatability — starting by defining the magnitude of the issue, identifying key challenges, and then discussing perceived solutions and remaining risks across science, regulation, and policy.

Guest: Dr Daniel Levner, Co-Founder & CTO at Emulate Inc.

Daniel is the Chief Technology Officer at Emulate. A serial deep-tech entrepreneur, Levner co-founded Emulate and brings to it extensive experience in biological and engineering technology development and commercialization. Levner joined the Emulate founding team during his role as a Senior Staff Scientist with the Wyss Institute for Biologically Inspired Engineering at Harvard University. There, he led the advanced engineering team responsible for developing the Emulate Organ-Chip platform and played a key leadership role formulating innovative approaches for bridging biologists, engineers and business stakeholders. Daniel received his PhD in electrical engineering from Stanford University as well as an MS in aeronautics and astronautics, also from Stanford. He has authored numerous publications and more than 70 issued and pending US patents. Q&A: you can submit questions ahead on the registration form below.

Facilitator: Dr. Zaher Nahle, CHE & Ivyctory Solutions

Zaher Nahle is an interdisciplinary executive scientist with senior leadership experience across biomedical research, academia, and public policy, including roles as Chief Scientific Officer, Vice President for Research, and CEO at major U.S. medical foundations. He earned his PhD in Physiology and Biophysics from the Stony Brook University/Cold Spring Harbor Laboratory joint program, his Master’s in Public Administration from Harvard University, and his certificate in Public Policy and Management from Harvard Kennedy School, where he was a Mason Fellow. A former faculty member at Vanderbilt and Cornell, he has published extensively in leading journals and pioneered high-throughput technologies such as gene microarrays. He currently serves as Senior Scientific Advisor to the Center for a Humane Economy and Animal Wellness Action and is the founder of the IVYCTORY Group.